Kopaq (Iohexol)

Iohexol works by providing a high concentration of iodine atoms that absorb X‑ray photons. When injected, it increases the radiodensity of the blood, tissues, or cerebrospinal fluid, creating a clear contrast between the enhanced structures and surrounding anatomy, which allows detailed imaging.

The dose of Kopaq is individualized. The prescribing physician determines the volume and concentration based on the specific imaging study, patient weight, renal function, and the route of administration. No standard dose is provided in public literature.

Kopaq is classified as Pregnancy Category B, indicating that animal studies have not shown risk to the fetus and there are no adequate human studies. It may be used when clearly needed, but the prescriber should evaluate the benefit‑risk balance for each pregnant or breastfeeding patient.

To order Kopaq, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Kopaq (Iohexol) is a non‑ionic, low‑osmolality iodinated contrast agent, offering a favorable safety profile compared with older high‑osmolality agents. Compared with other low‑osmolality agents such as iopamidol or iopromide, Iohexol provides similar image quality and is widely used for a broad range of vascular and body imaging studies.

Kopaq should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from direct sunlight, moisture, and extreme temperature fluctuations. Do not freeze the solution, and ensure the container is sealed until use.

Kopaq is administered by a qualified healthcare professional via intravenous, intra‑arterial, or intrathecal injection, depending on the imaging modality. The injection is performed under controlled conditions, with appropriate monitoring of the patient’s vital signs throughout the procedure.

The most serious risks include severe allergic reactions such as anaphylaxis, acute renal impairment (contrast‑induced nephropathy), cardiac arrhythmias, and pulmonary edema. Immediate medical attention is required if any of these reactions occur during or after administration.

Kopaq should be avoided in patients with a known hypersensitivity to iodinated contrast media, severe renal insufficiency (eGFR < 30 mL/min/1.73 m²), uncontrolled hyperthyroidism, or in those who have experienced a prior severe reaction to any iodinated contrast agent.